Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 11, 2010, Pages 1915-1923

  Mukherji, Deborah ^a   Pettengell, Ruth ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Aggressive non Hodgkin lymphoma; Anthracycline; Pixantrone; Relapsed refractory non Hodgkin's lymphoma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; LENALIDOMIDE; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PIXANTRONE; PREDNISOLONE; RITUXIMAB; SORAFENIB; VINCRISTINE; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE;

ALOPECIA; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FEBRILE NEUTROPENIA; HEART FAILURE; HUMAN; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; THROMBOCYTOPENIA; URINE VOLUME; VOMITING; ANIMAL; CLINICAL TRIAL (TOPIC); LYMPHOMA, NON-HODGKIN;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; ISOQUINOLINES; LYMPHOMA, NON-HODGKIN;

EID: 77954792043     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.494180     Document Type: Review

References (51)

1. American Cancer Society. Cancer facts and figures 2009. Atlanta: American Cancer Society; 2009
2. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 2002;94:2015-2023
3. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-1677
4. van Dalen EC, van der Pal HJ, Bakker PJ, et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 2004;40:643-652
5. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The MD Anderson cancer centre experience. Hematol Oncol Clin North Am 1997;11:937-947
6. Jerkeman M, Leppa S, Kvaloy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive lymphoma - the Nordic Lymphoma Group experience. Eur J Haematol 2004;73:179-182
7. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-122
8. Reiser M, Schnell R, Straub G, et al. DIZE (dexamethasone, idarubicin and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk Lymphoma 1998;31:359-366
9. Wheeler RH, Ensminger WD, Thrall JH, et al. High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia. Cancer Treat Rep 1982;66:493-498
10. Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006;47:2174-2180
11. Macpherson N, Belch A, Taylor M, et al. Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: a phase II study. Leuk Lymphoma 2006;47:1327-1332
12. Rigacci L, Mappa S, Nassi L, et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamde, vincristine, prednisolone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Haematol Oncol 2007;25:198-203
13. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004;130:1-7
14. Galetta F, Franzoni F, Cervetti G, et al. Effect of epirubicin-based chemotherapy and dextrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 2005;59:541-544
15. Witzig TE, Vose JM, Zinzani PL, et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-50130NHL-003). Blood 2009;114:abstract 1676
16. Guidetti A, Carlo-Stella C, Devizzi L, et al. Preliminary results of a phase II trial with the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood 2009;114:abstract 1658
17. Stopeck AT, Unger JM, Rimsza LM, et al. A Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009;50:728-735
18. Ansell SM, Inwards D, Rowland K Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a Phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113:508-514
19. Rizzieri D, Feldman E, Dipersio J, et al. A Phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14:2756-2762
20. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675
21. Friedberg LW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585
22. Crump M, Coiffier B, Jacobsen E, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19:964-969
23. Wilson W, O'Connor O, Czuczman M, et al. Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies. Blood 2008;112:abstract 2108
24. Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008;143:355-360
25. Denny WA, Wakelin LPG. Kinetics and binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and antitumour activity. Anti Cancer Drug Des 1990;5:189-200
26. De Isabella P, Palumbo M, Sissi C, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity and physico-chemical properties of 2-aza and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 1995;48:30-38
27. Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of aza-anthracenedione- induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol 1995;50:1087-1094
28. Zwelling LA, Mayes J, Cltschuler E, et al. Activity of two novel antrhracene-9,10-diones against human leukaemia cells containing inercalator-sensitive or -resistant forms of topoisomerase II. Biochem Pharmacol 1993;46:265-271
29. Evison BJ, Mansour OC, Menta E, et al. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res 2007;35:3581-3589
30. Evison BJ, Chiu F, Pezzoni G, et al. Formaldehyde-activated pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol 2008;74:184-194
31. Evison BJ, Bilardi RA, Chiu F, et al. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res 2009;37:6355-6370
32. Beggiolin G, Crippa L, Menta E, et al. BBR 2778, an anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001;87:407-416
33. Cavalletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007;25:187-195
34. Faivre S, Raymond E, Boige V, et al. A Phase 1 and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 2001;7:43-50
35. Dawson LK, Jodrell DI, Bowman A, et al. A clinical phase 1 and pharmacokinetic study of BBR 2778, a novel anthracenidone analogue, administered intravenously, 3 weekly. Eur J Cancer 2000;36:2353-2359
36. Borchmann P, Schnell R, Knippertz R, et al. Phase 1 study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:6617
37. Josting A, Reiser M, Ruffer U, et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 2000;18:322-329
38. Borchmann P, Morschhauser F, Parry A, et al. Phase II study of the new aza-anthracenidone, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematolgia 2003;88:888-894
39. Borchmann P, Schnell R, Morschhauser F, et al. A Phase 1 study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisolone in patients with relapsed non-Hodgkin's lymphoma. Blood 2003;102:abstract 2369
40. Borchmann P, Herbrecht R, Wilhelm M, et al. Results of a phase II study of pixantrone in combination with cyclophosphamide, vincristine and prednisolone in patients with relapsed aggressive non-Hodgkin's lymphoma. Blood 2006;108:abstract 529
41. Lim ST, Hayad L, Tulpule A, et al. A phase I/II trial of pixantrone (BBR2778), methyprednisolone, cisplatin and cytosine arabinoside (PSAHP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2007;48:374-380
42. Pettengell R, Coiffier B, Narayanan G, et al. Phase III trial of pixantrone dimaleate compared with other agents as third-line, single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma (EXTEND): results from the treatment and follow-up periods. Blood 2009;114:abstract 1677
43. US Food and Drug Administration (FDA). Available from: www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/ ucm199558.htm [Last accessed 6 May 2010]
44. Swain SM, Whaley T, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-2879
45. US Food and Drug Administration (FDA). Available from: www.fda.gov/ downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/ UCM206082.pdf [Last accessed 6 May 2010]
46. Herbrecht R, Couban S, Weissinger F, et al. CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituximab) in first-line therapy of diffuse large B-cell lymphoma (DLBCL); an interim analysis. Blood 2007;110:abstract 3445
47. Santoro A, Voglova J, Gabrail N, et al. Comparative trail of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/ refractory indolent non-Hodgkin's lymphoma (NHL). J Clin Oncol 2006;24:abstract 7578
48. Fayad L, Liebmann J, Modiano M, et al. Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone and rituximab in the treatment of patients with relapsed/ refractory indolent non-Hodgkin's lymphoma (NHL). Blood 2006;108:abstract 2758
49. Gonsette RE. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opin Pharmacother 2007;8:1103-1116
50. Mordente A, Meucci E, Silvestrini A, et al. New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 2009;16:1656-1672
51. Hacker M, McKennon M, Singer J. Lack of iron binding by pixantrone is associated with reduced production of reactive oxygen species and myocyte cytotoxicity in vitro. Blood 2009;114:abstract 4806